Clearmind Achieves Key Milestones in 2025 FDA-Approved Clinical Trials
The company said, "Throughout 2025, Clearmind achieved critical milestones in its FDA-approved Phase I/IIa clinical trial for CMND-100, a proprietary non-hallucinogenic MEAI-based oral compound designed to address AUD-a condition affecting millions worldwide with limited effective treatment options. Key 2025 highlights include: Clinical Trial Progress: Advanced the multinational Phase I/IIa trial with site activations at prestigious institutions, including Yale School of Medicine, Johns Hopkins University School of Medicine, Tel Aviv Sourasky Medical Center, and Hadassah Medical Center. The Company successfully initiated first-in-human dosing, completed treatment and enrollment for the first cohort, and reported positive top-line safety and tolerability results with no serious adverse events. Additionally, the first patients in the Israeli sites were enrolled and successfully dosed. Moreover, Clearmind completed enrollment and dosing for the second cohort, accelerating the path toward further data readouts. Independent Safety Endorsement: Received unanimous approval from the Data and Safety Monitoring Board to continue the Phase I/IIa clinical trial following an interim review, reinforcing CMND-100's favorable safety profile. Global Footprint Expansion: Strengthened intellectual property portfolio and pipeline of its non-hallucinogenic neuroplastogen patents with multiple international patent filings and publications targeting indications such as weight loss, obesity, metabolic disorders, depression, PTSD, anxiety and binge behaviors."
Get Free Real-Time Notifications for Any Stock
Analyst Views on CMND
About CMND
About the author
Clearmind Regains Nasdaq Compliance with Share Price Above $1
- Compliance Restoration: Clearmind Medicine confirmed on December 30, 2025, that its common shares have maintained a closing price above $1 for the last 10 consecutive trading days, successfully regaining compliance with Nasdaq Listing Rule 5550(a)(2), indicating positive progress in stock price stability.
- Price Volatility Context: Previously, Clearmind was notified on December 4, 2025, of non-compliance due to its share price being below $1 for over 30 consecutive trading days, and this compliance restoration is expected to enhance investor confidence and attract more capital inflow.
- Market Reaction Expectations: With the restoration of compliance, Clearmind is likely to improve its market image and bolster investor confidence in its future growth potential, particularly in light of its commitment to developing novel psychedelic treatment solutions.
- Strategic Development Focus: Clearmind is currently focused on developing neuroplastic drugs targeting under-treated health issues and will continue to seek patent protection to enhance its intellectual property portfolio, further strengthening its competitiveness in the biotech sector.
Clearmind Regains Nasdaq Compliance with Share Price Above $1
- Compliance Regained: Clearmind Medicine received confirmation from Nasdaq on December 30, 2025, that its share price exceeded $1 for the last 10 consecutive trading days, thereby regaining compliance with Nasdaq Listing Rule 5550(a)(2) and resolving previous compliance issues.
- Price Fluctuation Context: The company was notified on December 4, 2025, of non-compliance due to its common shares closing below $1 for over 30 consecutive trading days, highlighting market concerns regarding its stock price volatility.
- Future Growth Potential: Clearmind focuses on developing novel neuroplastogen-derived therapeutics, particularly for alcohol use disorder, which is expected to attract more investor interest in its innovative treatment solutions, further stabilizing and potentially increasing the company's stock price.
- Intellectual Property Strategy: The company currently holds 19 patent families and 31 granted patents, with plans to seek additional patents to enhance its market competitiveness, demonstrating a long-term strategic vision in the biotechnology sector.
